title: Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
abstract: Dermatologic toxicity is a known reaction of ipilimumab and vemurafenib. Because of the lack of effective treatments and aggressive nature of melanoma, treatments are often discontinued and new treatments are initiated in rapid succession. We report what we believe to be the first case of cumulative dermatologic toxicity secondary to rapid-sequential treatment with ipilimumab and vemurafenib for metastatic melanoma that responded to high-dose steroids. This case highlights the combined toxicity of these two drugs that can occur as a result of overlapping toxicity. It also illustrates the need for a substantial wash out period between rapid cycling of these two drugs secondary to ipilimumab's long half-life.
authors.affiliation: Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Ludlow
authors.forename: Yanina
authors.initials: Y
authors.lastname: Pasikhova
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005076:Exanthema / Q000139:chemically induced / Q000628:therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008775:Methylprednisolone / Q000627:therapeutic use*; D009154:Mutation; D009362:Neoplasm Metastasis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D013449:Sulfonamides / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D008775:Methylprednisolone